Blinded independent central reviews: The FDA weighs in

Author： Walovitch Richard C.  

Publisher： Informa Healthcare

ISSN： 1060-1333

Source： Clinical Research and Regulatory Affairs, Vol.30, Iss.3, 2013-09, pp. : 33-37

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of Discordance Measures in Oncology Studies with Blinded Independent Central Review of Progression-Free Survival Using an Observational Error Model

By Mannino F. V.   Amit O.   Lahiri S.  

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 5, 2013-09 ,pp. : 971-985

Taylor & Francis Ltd

Access to resources Recommend Favorite

FDA reviews safety of somatropin

By  

Reactions Weekly, Vol. 1, Iss. 1334, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

FDA reviews Xyrem-related deaths

By  

Reactions Weekly, Vol. 1, Iss. 1433, 2013-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

US FDA reviews safety of Stalevo

By  

Reactions Weekly, Vol. 1, Iss. 1297, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

FDA reviews link between pramipexole and heart failure

By  

Reactions Weekly, Vol. 1, Iss. 1421, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite